Lead
Development Projects
Personalized Medicine
Using proprietary technology to enable the rapid and affordable targeting of patient-specific cancer cells and paraproteins
Status: Screening of ex-vivo samples from multiple-myeloma patient
Targeted Destruction of Cancer Cells
Targeted destruction of cancerous cells using in-licensed Mozaic & Lexcicon drug discovery technologies
Status: Positive in vitro work with 3rd party on ovarian cancer cell lines
Oral Granulocyte Colony Stimulating Factor
The oral delivery of GCSF could supplement injected products currently on the market and expand the market through greater patient compliance and acceptance
Status: Preparing for pre-clinical studies
Oral Interferon
Could replace injected interferon products currently on the market for cancer indications and expand market through greater patient acceptance
Status: Preparing for formulation studies
|